Artelo Biosciences, Inc.

NasdaqCM:ARTL Stock Report

Market Cap: US$1.4m

Artelo Biosciences Management

Management criteria checks 2/4

Artelo Biosciences' CEO is Greg Gorgas, appointed in Apr 2017, has a tenure of 9.08 years. total yearly compensation is $1.22M, comprised of 44.1% salary and 55.9% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $1.66K. The average tenure of the management team and the board of directors is 7 years and 7.5 years respectively.

Key information

Greg Gorgas

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage44.14%
CEO tenure9.1yrs
CEO ownership0.1%
Management average tenure7yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

Seeking Alpha • Aug 16

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Nano-cap stock Artelo Biosciences (NASDAQ:ARTL) added ~21% in the morning hours Tuesday after the clinical-stage pharma announced the recent publication of preclinical data supporting the potential of its FABP inhibitor therapeutic platform in anxiety-related disorders. The research led by academics Taygun C. Uzuneser, Ph.D., and Steven R. Laviolette, Ph.D., at the University of Western Ontario, London, Ontario, is based on one of Artelo’s (ARTL) FABP inhibitors. As published in the journal Cerebral Cortex, the pre-clinical indicate that a fatty acid binding protein 5 (FABP5) inhibitor from ARTL’s FABP inhibitor platform lessens the anxiety behaviors in a section of the brain important for anxiety. In addition, the research highlights the prospects of modulation of the FABP5 system as a target in developing novel anxiolytics. “This new data further supports the development of our FABP inhibitor platform in anxiety-related disorders such as post-traumatic stress disorder,” Chief Executive of Artelo (ARTL) Gregory D. Gorgas noted. Read: A pre-clinical data readout supporting its product candidate ART27.13 sent ARTL shares sharply higher in April.
Analysis Article • Mar 28

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 09

Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

Over 10 million people are stricken by cancer each year, with as much as 60% suffering from loss of appetite or anorexia and wasting disease or cachexia. With no standard of care available to treat patients with cancer-related anorexia, there is an eager patient population ready for an effective treatment. Phase Ia/Ib clinical trial of Artelo’s ART27.13 compound is fully enrolled and final data could be available for year-end 2022, providing proof of efficacy among cancer patients suffering from anorexia. Capital raise in late 2021 has provided sufficient capital resources to support Artelo through the completion of the required Phase II clinical trials for its ART27.13. Using potential competitors and peers with publicly traded stock to provide comparable valuation metrics, ARTL is found to have intrinsic value well above its current stock price.
Analysis Article • Nov 02

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 12

Relief For Cancer Patients In Artelo Bioscience Pipeline

Exciting opportunities are emerging for new therapies that target the recently identified endocannabinoid system, which governs numerous cellular processes in human body. To economically build portfolio value, Artelo’s business model relies on both in-licensed and internally developed compounds and contracts for clinical services. Patents awarded to Artelo protect two promising small molecule candidates and a cocrystal of cannabidiol. Human clinical trials are underway for a therapeutic candidate targeting cancer-related anorexia, a worrisome condition that has no established treatment and a market value expected to grow near 10% CAGR through 2030. Artelo has sufficient capital resources to reach its next value-generating milestone at the end of the Phase 1b/2a clinical trial for cancer-related anoxia therapy. Favorable clinical trial data could serve as strong valuation catalyst.
Analysis Article • May 20

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 04

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

CEO Compensation Analysis

How has Greg Gorgas's remuneration changed compared to Artelo Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$13m

Dec 31 2025US$1mUS$540k

-US$13m

Sep 30 2025n/an/a

-US$12m

Jun 30 2025n/an/a

-US$11m

Mar 31 2025n/an/a

-US$10m

Dec 31 2024US$1mUS$520k

-US$10m

Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$994kUS$485k

-US$9m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$9m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$655kUS$440k

-US$10m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$12m

Dec 31 2021US$1mUS$142k

-US$12m

Nov 30 2021n/an/a

-US$9m

Aug 31 2021n/an/a

-US$7m

May 31 2021n/an/a

-US$7m

Feb 28 2021n/an/a

-US$5m

Nov 30 2020n/an/a

-US$5m

Aug 31 2020US$581kUS$431k

-US$5m

May 31 2020n/an/a

-US$4m

Feb 29 2020n/an/a

-US$4m

Nov 30 2019n/an/a

-US$3m

Aug 31 2019US$347kUS$209k

-US$2m

Compensation vs Market: Greg's total compensation ($USD1.22M) is above average for companies of similar size in the US market ($USD629.02K).

Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.

CEO

Greg Gorgas (62 yo)

9.1yrs
Tenure
US$1,223,455
Compensation

Mr. Gregory D. Gorgas, also known as Greg, M.B.A. has been the Chief Executive Officer, President, Secretary of Artelo Biosciences, Inc. since April 3, 2017 and served as its Treasurer until November 01, 2...

Leadership Team

NamePositionTenureCompensationOwnership
Gregory Gorgas
President9.1yrsUS$1.22m0.12%
$ 1.7k
Mark Spring
CFO, Treasurerless than a yearUS$290.54k0%
$ 0
Andrew Yates
Senior VP & Chief Scientific Officer5.3yrsno datano data
Steven Reich
Chief Medical Officer8.1yrsno datano data
Jason Baybutt
Senior Vice President of Finance7yrsno datano data
7.0yrs
Average Tenure
64yo
Average Age

Experienced Management: ARTL's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gregory Gorgas
President9.1yrsUS$1.22m0.12%
$ 1.7k
Connie Matsui
Independent Chairperson of the Board9yrsUS$76.50k0.022%
$ 306.5
Robert Emanuele
Independent Director8.7yrsUS$44.00k0.0050%
$ 68.6
Tamara Favorito
Independent Director5.2yrsUS$60.00k0%
$ 0
Steven Kelly
Independent Director9yrsUS$59.50k0.0050%
$ 68.6
Iwao Ojima
Member of the Advisory Board4.6yrsno datano data
Gregory Reyes
Independent Director5.5yrsUS$45.00k0%
$ 0
Richard Porter
Member of Scientific Advisory Board5.4yrsno datano data
Douglas Blayney
Independent Director8.8yrsUS$48.00k0.0050%
$ 68.6
Steven Laviolette
Member of Scientific Advisor Boardno datano datano data
Martin Kaczocha
Member of Scientific Advisory Board6.4yrsno datano data
7.5yrs
Average Tenure
71yo
Average Age

Experienced Board: ARTL's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/29 16:46
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Artelo Biosciences, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group